MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-024-02445-x

Медицинская библиотека · Leukemia · 2024

Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.

Shimoni Avichai, Peczynski Christophe, Labopin Myriam, Kulagin Alexander, Meijer Ellen, Cornelissen Jan, Choi Goda, Sanz Jaime, Rovira Montserrat, Van Gorkom Gwendolyn, Kröger Nicolaus, Koc Yener, Vydra Jan, Diez-Martin J L, Solano Carlos, Patel Amit, Chiusolo Patrizia, Ciceri Fabio, Nagler Arnon, Mohty Mohamad

СтатьяПеревод в очереди

Аннотация

The association of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects after allogeneic stem-cell transplantation (SCT) is well-established but was not confirmed in the modern era and following post-transplant cyclophosphamide (PTCy). We assessed GVHD/ GVL association in AML patients following HLA-matched SCT with standard calcineurin-based (n = 12,653, 57% with additional in-vivo T-cell depletion) or PTCy-based (n = 508) GVHD prophylaxis. Following standard prophylaxis, acute GVHD grade II-IV and III-IV, chronic GVHD, and extensive chronic GVHD rates were 23.8%, 7.5%, 37.0%, and 16.3%, respectively. Acute GVHD grade II and III-IV were associated with lower relapse [hazard-ratio (HR) 0.85, P = 0.002; HR 0.76, P = 0.003, respectively)], higher non-relapse mortality (NRM) (HR 1.5, P < 0.001; HR 6.21, P < 0.001) and lower overall survival (OS) (HR 1.49, P < 0.001; HR 6.1, P < 0.001). Extensive chronic GVHD predicted lower relapse (HR 0.69, P < 0.001), higher NRM (HR 2.83, P < 0.001), and lower OS (HR 2.74, P < 0.001). Following PTCy, GVHD rates were 22.8%, 6.2%, 35.5%, and 17.7%, respectively. Acute GVHD was not associated with relapse (HR 1.37, P = 0.15) but predicted higher NRM (HR 3.34, P < 0.001) and lower OS (HR 1.92, P = 0.001). Chronic GVHD was not prognostic for these outcomes. In conclusion, GVHD and GVL are strongly associated with contemporary SCT. However, following PTCy, GVHD is not associated with reduced relapse.

Для цитирования: Shimoni Avichai, Peczynski Christophe, Labopin Myriam, Kulagin Alexander, Meijer Ellen, Cornelissen Jan, Choi Goda, Sanz Jaime, Rovira Montserrat, Van Gorkom Gwendolyn, Kröger Nicolaus, Koc Yener, Vydra Jan, Diez-Martin J L, Solano Carlos, Patel Amit, Chiusolo Patrizia, Ciceri Fabio, Nagler Arnon, Mohty Mohamad. Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.. Leukemia. 2024. DOI: 10.1038/s41375-024-02445-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.